Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children

Research in Developmental Disabilities

Volumn 30, Issue 2, 2009, Pages 386-396

  Aman, Michael G ^a   Hollway, Jill A ^a   Leone, Sarah ^a   Masty, Jessica ^a   Lindsay, Ronald ^a   Nash, Patricia ^a   Arnold, L Eugene ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Behavior ratings; Children; Cognitive functioning; Motor performance

Indexed keywords

PLACEBO; RISPERIDONE;

ADOLESCENT; ANALYSIS OF VARIANCE; ARTICLE; ATTENTION; BODY WEIGHT; CHECKLIST; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISRUPTIVE BEHAVIOR; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DYSKINESIA; FEMALE; HEART RATE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPONSE TIME; SEAT; SHORT TERM MEMORY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; VISION; VITAL SIGN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD, PRESCHOOL; COGNITION; DOPAMINE ANTAGONISTS; DYSKINESIAS; FEMALE; HUMANS; MALE; MOTOR SKILLS; RISPERIDONE;

EID: 57149111476     PISSN: 08914222     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ridd.2008.07.004     Document Type: Article

References (43)

1. Aman M.G. Drugs and learning in mentally retarded persons. In: Burrows G.D., and Werry J.S. (Eds). Advances in human psychopharmacology Vol. 3 (1984), JAI Press, Greenwich, CT 121-163
2. Aman M.G. Applications of computerized cognitive-motor measures to the assessment of psychoactive drugs. In: Dodson W.E., Kinsbourne M., and Hiltbrunner B. (Eds). The assessment of cognitive function in epilepsy (1991), Demos Publications, New York 69-96
3. Aman M.G., and Singh N.N. Aberrant behavior checklist-community. Supplementary manual (1994), Slosson Educational Publications, East Aurora, NY
4. Aman M.G., Singh N.N., Stewart A.W., and Field C.J. The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency 89 (1985) 485-491
5. Aman M.G., Singh N.N., Stewart A.W., and Field C.J. Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency 89 (1985) 492-502
6. Aman M.G., Marks R.E., Turbott S.H., Wilsher C.P., and Merry S.N. Methylphenidate and thioridazine in the treatment of intellectually subaverage children: Effects on cognitive-motor performance. Journal of the American Academy of Child and Adolescent Psychiatry 30 (1991) 816-824
7. Aman M.G., Kern R.A., McGhee D.E., and Arnold L.E. Fenfluramine and methylphenidate in children with mental retardation and attention deficit hyperactivity disorder: Laboratory effects. Journal of Autism and Developmental Disorders 23 (1993) 491-506
8. Aman M.G., Tasse M.J., Rojahn J., and Hammer D. The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities 17 (1995) 41-57
9. Aman M.G., DeSmedt G., Derivan A., Lyons B., Findling R.L., and the Risperidone Disruptive Behavior Study Group. Double-blind placebo-controlled study of risperidone for the treatment of disruptive behavior in children iwth subaverage intelligence. American Journal of Psychiatry 159 (2002) 1337-1346
10. Aman M.G., Arnold L.E., McDougle C.J., Vitiello B., Scahill L., Davies M., et al. Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology 15 6 (2005) 869-884
11. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry 159 6 (2002) 1018-1028
12. Borison R.L. The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatrica Scandinavica (Supplement) 389 (1996) 5-11
13. Botteron K., and Geller B. Disorders, symptoms, and their pharmacotherapy. In: Werry J.S., and Aman M.G. (Eds). Practitioner's guide to psychoactive drugs for children and adolescents (1998), Plenum, New York 183-209
14. Cuesta M.J., Paealta V., and Zarzuela A. Effects of olanzapine and other antipsychocitcs on cognitive function in chronic schizophrenia: A longitudinal study. Schizophrenia Research 48 (2001) 17-28
15. Ernst M., Malone R.P., Rowan A.B., George R., Gonzalez N.M., and Silva R.R. Antipsychotics (neuroleptics). In: Werry J.S., and Aman M.G. (Eds). Practitioner's guide to psychoactive drugs for children and adolescents (1999), Plenum, New York 297-327
16. Findling R.L., Aman M.G., DeSmedt G., Derivan A., Lyons B., and the Risperidone Disruptive Behavior Study Group. A long-term open-label study of risperidone in children with severe disruptive behaviors and subaverage IQ. American Journal of Psychiatry 161 (2004) 677-684
17. Gallhofer B., Bauer U., Lis S., Krieger S., and Gruppe H. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. European Neuropsychopharmacology 6 Suppl. (1996) S13-S20
18. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal 321 (2000) 1371-1376
19. Green M.F., Marshall B.D., Wirshing W.C., Ames D., Marder S.R., McGurk S., et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. American Journal of Psychiatry 154 (2000) 700-804
20. Gunther T., Herpertz-Dahlman B., Jolles J., and Konrad K. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and comorbid disruptive behavior disorder. Journal of Child and Adolescent Psychopharmacology 16 (2006) 725-735
21. Honey G.D., Bullmore E.T., Soni W., Varatheesan M., Williams S.C.R., and Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proceedings of the National Academy of Sciences 96 (1999) 13432-13437
22. Kaufman A.S., and Kaufman N.L. Kaufman Brief Intelligence Test (K-BIT), manual and easel (1990), American Guidance Service, Circle Pines, MN
23. Keefe R.S.E., Silva S.G., Perkins D.O., and Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitve impairment in schizophrenia: A review and meta-analysis. Schizophrenia Bulletin 25 (1999) 201-222
24. Kløve H. Clinical neuropsychology. In: Forster F.M. (Ed). The medical clinics of North America Vol. 47 (1963), Saunders, New York 1647-1658
25. MacQueen G., and Young T. Cognitive effects of atypical antipsychotics: Focus on bipolar spectrum disorders. Bipolar Disorders 56 (2003) 53-61
26. Martin A., et al. Weight and leptin changes among risperidone-treated youths with autism: Six-month prospective data. American Journal of Psychiatry 161 (2004) 1125-1127
27. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clinical Neuroscience 3 (1995) 64-75
28. Mori K., Nagao M., Yamashita H., Morinobu S., and Yamawaki S. Effect of switching antipsychotics on memory in patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28 (2004) 659-665
29. NIMH (1985). AIMS (Abnormal Involuntary Movement Scale). Psychopharmacology Bulletin, (Special feature on Rating Scales and Assessment Involvements for Use in Pediatric Psychopharmacology Research), 21, 1077-1080.
30. Pandina G.J., Bilder R., Harvey P.D., Keefe R.S.E., Aman M.G., and Gharabawi G. Risperidone and cognitive function in children with disruptive behavior disorders. Biological Psychiatry 62 (2007) 226-234
31. Purdon S.E. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophrenia Research 35 (1999) S51-S60
32. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S., et al. Neuropscychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Archives of General Psychiatry 57 (2000) 249-258
33. Research Units on Pediatric Psychopharmacology Autism Network (2002). A double-blind, placebo-controlled trial of risperidone in children with autistic disorder. The New England Journal of Medicine, 347, 314-321.3.
34. Snyder R., Turgay A., Aman M.G., Binder C., Fisman S., Carroll A., et al. Effects of risperidone on conduct and disruptive behavior disorders n children with subaverage IQs. Journal of the American Academy of Child and Adolescent Psychiatry 41 (2002) 1026-1036
35. Sprague R.L., and Sleator E.K. Methylphenidate in hyperkinetic children: Differences in dose effects on learning and social behavior. Science 198 (1977) 1274-1276
36. Sprague R.L., and Toppe L.K. Relationship between activity level and delay of reinforcement. Journal of Experimental Psychology 3 (1966) 390-397
37. Stigler K.A., Potenza M.N., and McDougle C.J. Tolerability of atypical antipsychotics in children and adolescents. Paediatrica Drugs 3 (2001) 927-942
38. Stip E., Chouinard S., and Boulay L.J. On the trail of a cognitive enhancer for the treatment of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29 (2005) 219-232
39. Tandon R. Safety and tolerability: How do newer generation "atypical" antipsychotics compare?. Psychiatric Quarterly 73 (2002) 297-311
40. Thorndike R.L., Hagen E., and Sattler J. Guide for administering and scoring the fourth edition Stanford-Binet intelligence scale (1986), Riverside, Chicago
41. Toren P., Ratner S., Laor N., and Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety 27 14 (2004) 1135-1136
42. Troost P.W., Althaus M., Lahius B.E., Buitelaar J.K., Minderaa R.B., and Hoekstra P.J. Neuropsychological effects of risperidone in children with pervasive developmental disorders: A blinded discontinuation study. Journal of Child and Adolescent Psychopharmacology 16 (2006) 61-573
43. Wechsler D. Manual for the Wechsler Intelligence Scale for children. 3rd ed. (1991), The Psychological Corporation, San Antonio, TX